A detailed history of Morgan Stanley transactions in Valneva Se stock. As of the latest transaction made, Morgan Stanley holds 1,979 shares of VALN stock, worth $13,991. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,979
Previous 5,474 63.85%
Holding current value
$13,991
Previous $43,000 69.77%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.01 - $9.08 $24,499 - $31,734
-3,495 Reduced 63.85%
1,979 $13,000
Q1 2024

Aug 16, 2024

BUY
$6.64 - $10.76 $7,396 - $11,986
1,114 Added 25.55%
5,474 $43,000
Q1 2024

May 15, 2024

BUY
$6.64 - $10.76 $7,396 - $11,986
1,114 Added 25.55%
5,474 $43,000
Q4 2023

Aug 16, 2024

BUY
$9.88 - $13.82 $23,524 - $32,905
2,381 Added 120.31%
4,360 $45,000
Q4 2023

Feb 13, 2024

BUY
$9.88 - $13.82 $4,940 - $6,910
500 Added 12.95%
4,360 $45,000
Q3 2023

Nov 15, 2023

BUY
$11.36 - $15.85 $5,680 - $7,925
500 Added 14.88%
3,860 $44,000
Q2 2023

Aug 14, 2023

BUY
$9.45 - $16.98 $944 - $1,698
100 Added 3.07%
3,360 $49,000
Q1 2023

May 15, 2023

SELL
$9.98 - $15.89 $17,035 - $27,124
-1,707 Reduced 34.37%
3,260 $33,000
Q4 2022

Feb 14, 2023

SELL
$10.38 - $14.87 $3,072 - $4,401
-296 Reduced 5.62%
4,967 $63,000
Q3 2022

Nov 14, 2022

SELL
$9.8 - $23.35 $29,027 - $69,162
-2,962 Reduced 36.01%
5,263 $53,000
Q2 2022

Oct 27, 2022

SELL
$13.71 - $37.57 $25,980 - $71,195
-1,895 Reduced 18.73%
8,225 $186,000
Q2 2022

Aug 15, 2022

SELL
$13.71 - $37.57 $25,980 - $71,195
-1,895 Reduced 18.73%
8,225 $186,000
Q1 2022

Oct 27, 2022

BUY
$27.0 - $50.99 $51,165 - $96,626
1,895 Added 23.04%
10,120 $347,000
Q1 2022

May 13, 2022

SELL
$27.0 - $50.99 $282,717 - $533,916
-10,471 Reduced 50.85%
10,120 $347,000
Q4 2021

Feb 14, 2022

BUY
$27.1 - $67.28 $474,277 - $1.18 Million
17,501 Added 566.38%
20,591 $1.14 Million
Q3 2021

Nov 15, 2021

BUY
$25.02 - $53.38 $77,311 - $164,944
3,090 New
3,090 $97,000

Others Institutions Holding VALN

About Valneva SE


  • Ticker VALN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,103,504
  • Market Cap $489M
  • Description
  • Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; ...
More about VALN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.